复方金戟颗粒治疗原发性早泄(肝郁肾虚证)的多中心、随机、双盲、双模拟临床研究

注册号:

Registration number:

ITMCTR2200005688

最近更新日期:

Date of Last Refreshed on:

2022-03-09

注册时间:

Date of Registration:

2022-03-09

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

复方金戟颗粒治疗原发性早泄(肝郁肾虚证)的多中心、随机、双盲、双模拟临床研究

Public title:

a Random, Double-blind, Double-simulation, Multicenter study of Chinese Herbal Compound Jinji Granules (CJG) for treatment Primary Premature Ejaculation: (Gan depression an Shen deficiency syndrome)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

复方金戟颗粒治疗原发性早泄(肝郁肾虚证)的多中心、随机、双盲、双模拟临床研究

Scientific title:

a Random, Double-blind, Double-simulation, Multicenter study of Chinese Herbal Compound Jinji Granules (CJG) for treatment Primary Premature Ejaculation: (Gan depression an Shen deficiency syndrome)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200057359 ; ChiMCTR2200005688

申请注册联系人:

赵丰

研究负责人:

王福

Applicant:

Zhao Feng

Study leader:

Wang Fu

申请注册联系人电话:

Applicant telephone:

15270816079

研究负责人电话:

Study leader's telephone:

13426071953

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

493600550@qq.com

研究负责人电子邮件:

Study leader's E-mail:

fu311306@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区西苑操场1号

研究负责人通讯地址:

北京市海淀区西苑操场1号

Applicant address:

1 Caochang, xiyuan, Beijing, People's Republic of China

Study leader's address:

1 Caochang, xiyuan, Beijing, People's Republic of China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院西苑医院

Applicant's institution:

Xiyuan Hospital of China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021XLA127-3

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中国中医科学院西苑医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of Xiyuan Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2022/2/17 0:00:00

伦理委员会联系人:

訾明杰

Contact Name of the ethic committee:

Zi Mingjie

伦理委员会联系地址:

北京市海淀区西苑操场1号

Contact Address of the ethic committee:

1 Caochang, xiyuan, Beijing, People's Republic of China

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-62835646

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院西苑医院

Primary sponsor:

Xiyuan Hospital of China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市海淀区西苑操场1号

Primary sponsor's address:

1 Caochang, xiyuan, Beijing, People's Republic of China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

中国中医科学院西苑医院

具体地址:

北京市海淀区西苑操场1号

Institution
hospital:

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Address:

1 Caochang, xiyuan, Beijing, People's Republic of China

经费或物资来源:

中国中医科学院科技创新工程项目

Source(s) of funding:

Scientific and technological innovation project of China Academy of Chinese Medical Sciences

研究疾病:

早泄

研究疾病代码:

Target disease:

Premature ejaculation

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

采用多中心、随机、双盲、双模拟的试验设计,观察复方金戟颗粒治疗原发性早泄(肝郁肾虚证)的有效性和安全性。

Objectives of Study:

To study the efficacy and safety of compound Jinji granule in the treatment of primary premature ejaculation (Gan depression an Shen deficiency syndrome).

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合早泄西医诊断标准; (2)符合肝郁肾虚证中医辨证标准; (3)病程超过1年; (4)23岁≤年龄≤50岁; (5)性生活频率≥1次/周,每月至少6次性生活; (6)至少在最近 3 个月内及本研究过程中,受试者夫妻关系稳定或有稳定的成年女性性伴侣; (7)勃起功能正常,IIEF-5评分>21分; (8)受试者同意研究期间不使用任何其他早泄药物,包括5-ht抑制剂,中草药(包括汤剂、中成药),或用于治疗PE的器械; (9)受试者(包括伴侣)保证研究期间至最后一次给药后3个月内无生育计划且自愿采取适当避孕措施 (10)受试者自愿签署知情同意书。

Inclusion criteria

(1)Meet the diagnostic criteria of Western medicine for premature ejaculation; (2)Meet the standard of TCM syndrome differentiation. (3)The course of disease is more than 1 year. (4)23≤age≤50. (5)Sexual frequency≥1 time/week, at least 6 times a month. (6)At least in the last 3 months and during the course of this study, the subject had stable marital relationship or stable adult female sexual partner. (7)Normal erectile function, IIEF-5 score > 21 [20-23]. (8)Subjects agree not to use any other drugs for premature ejaculation during the study period, including 5-HT inhibitors, Chinese herbal medicines (including decoction and proprietary Chinese medicine), or devices used for PE treatment. (9)Subjects (including partners) guarantee that they have no birth plan and voluntarily use appropriate contraceptive measures during the study period up to 3 months after the last medication. (10)The subject voluntarily signs the informed consent.

排除标准:

(1)合并泌尿、生殖道感染患者,如尿道炎,前列腺炎等; (2)合并糖尿病和神经系统疾病的患者; (3)合并心血管疾病的患者; (4)合并肝肾功能不全的患者; (5)滥用精神类药品者; (6)合并有其他性功能障碍的患者; (7)正在使用其他药物进行治疗的患者。

Exclusion criteria:

(1)Patients with urinary and reproductive tract infection, such as urethritis, prostatitis, etc.; (2)Patients with diabetes and neurological diseases; (3)Patients with cardiovascular diseases; (4)Patients with liver and kidney dysfunction; (5)Persons who abuse psychotropic drugs; (6)Patients with other sexual dysfunction; (7)Patients who are being treated with other drugs.

研究实施时间:

Study execute time:

From 2021-10-01

To      2024-10-01

征募观察对象时间:

Recruiting time:

From 2022-03-10

To      2024-10-01

干预措施:

Interventions:

组别:

试验组

样本量:

46

Group:

Experimental group

Sample size:

干预措施:

复方金戟颗粒+达泊西汀模拟剂。复方金戟颗粒每日两次,每次一袋,早餐和晚餐后半小时,用温水冲泡后服用。 达泊西汀模拟剂,每次30mg,性生活前3小时。

干预措施代码:

Intervention:

Compound Jinji Granules(CJG)+Dapoxetine simulator.CGJ is taken twice a day, one bag at a time, half an hour after breakfast and dinner, and after brewing with warm water. Dapoxetine simulator,30mg each time, 3 hours before sexual life.

Intervention code:

组别:

对照组

样本量:

46

Group:

Control group

Sample size:

干预措施:

达泊西汀+复方金戟颗粒模拟剂。复方金戟颗粒模拟剂每日两次,每次一袋,早餐和晚餐后半小时,用温水冲泡后服用。 达泊西汀,每次30mg,性生活前3小时。

干预措施代码:

Intervention:

Dapoxetine+Compound Jinji Granules(CJG) simulation agent.CJG simulation agent is taken twice a day, one bag at a time, half an hour after breakfast and dinner, and after brewing with warm water. Dapoxetine,30mg each time, 3 hours before sexual life, oral 30mg.

Intervention code:

样本总量 Total sample size : 92

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

天津

Country:

China

Province:

Tianjin

City:

Tianjin

单位(医院):

天津市中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Three tertiary

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

中国中医科学院西苑医院

单位级别:

三级甲等

Institution/hospital:

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Level of the institution:

Three tertiary

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

首都医科大学附属北京中医医院

单位级别:

三级甲等

Institution/hospital:

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University

Level of the institution:

Three tertiary

国家:

中国

省(直辖市):

山东

市(区县):

济宁

Country:

China

Province:

Shandong

City:

Jining

单位(医院):

济宁市中西医结合医院

单位级别:

三级乙等

Institution/hospital:

Jining Hospital of Integrated Traditional Chinese and Western Medicine

Level of the institution:

Three tertiary

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Level of the institution:

Three tertiary

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省中医院

单位级别:

三级甲等

Institution/hospital:

Jiangsu Province Hospital of Chinese Medicine

Level of the institution:

Three tertiary

测量指标:

Outcomes:

指标中文名:

早泄谱

指标类型:

次要指标

Outcome:

Premature ejaculation Profile(PEP)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

Traditional Chinese medicine syndrome score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴道内射精潜伏期

指标类型:

主要指标

Outcome:

Intravaginal ejaculatory latency time(IELT)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床整体印象

指标类型:

次要指标

Outcome:

clinical global impression (CGI) of change

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Biood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 23
Min age years
最大 50
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

本试验采用区组随机化分组,随机分配编码由统计学专业人员采用SAS9.4软件生成随机数字分组表,实施时将纳入的病例按照试验病例随机编码表对应的序号进入对应的组别进行治疗观察。

Randomization Procedure (please state who generates the random number sequence and by what method):

This subject uses the random, the control method carries on the grouping design. In this study, block group randomization is used for grouping, and the random number grouping table is generated by statistics professionals using SAS9.4 software. During the implementation, the included cases are assigned to the c

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NO

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统